Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strategic Partners ASCHIX:STRAPC 27 Price-to-Tangible-Book is 18.23 as of Sep. 22, 2026. GuruFocus rates CHIX:STRAPC with a GF Score™ of 27/100. Among 1,133 Biotechnology companies, Strategic Partners AS ranks better than 78.46% on this metric.
The historical rank and industry rank for Strategic Partners AS's Price-to-Tangible-Book or its related term are showing as below:
CHIX:STRAPc'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.74 Med: 2.48 Max: 83.57
Current: 1.42
During the past 12 years, Strategic Partners AS's highest Price to Tangible Book Ratio was 83.57. The lowest was 0.74. And the median was 2.48.
CHIX:STRAPc's Price-to-Tangible-Book is ranked better than 78.46% of 1133
companies
in the Biotechnology industry
Industry Median: 3.29
vs CHIX:STRAPc: 1.42
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Strategic Partners AS Price-to-Tangible-Book Related Terms
Strategic Partners AS Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Strategic Partners AS's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strategic Partners AS Price-to-Tangible-Book Chart
CHIX:STRAPC vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Strategic Partners AS's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strategic Partners AS Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Strategic Partners AS's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Strategic Partners AS's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Strategic Partners AS (CHIX:STRAPC) has a Price-to-Tangible-Book of 18.23 as of Sep. 22, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Strategic Partners AS and its competitors. According to the industry distribution chart, Strategic Partners AS ranks #244 out of 1133 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Strategic Partners AS's Price-to-Tangible-Book too high?
Strategic Partners AS's current Price-to-Tangible-Book is 18.23. The Biotechnology industry median Price-to-Tangible-Book is 3.29. Strategic Partners AS's value of 18.23 is 454.1% above this industry median. Based on the distribution chart, Strategic Partners AS ranks #244 out of 1133 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Strategic Partners AS has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Strategic Partners AS's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Strategic Partners AS ranks #244 out of 1133 companies for Price-to-Tangible-Book. This places Strategic Partners AS in the top 22% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.29. Strategic Partners AS's value of 18.23 is 454.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.29, based on 1,133 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strategic Partners AS's current Price-to-Tangible-Book of 18.23 is 454.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Strategic Partners AS and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strategic Partners AS's current Price-to-Tangible-Book is 18.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strategic Partners AS stock overvalued right now?
Strategic Partners AS (CHIX:STRAPC) has a current Price-to-Tangible-Book of 18.23. The current Price-to-Tangible-Book is 18.23 and 454.1% above the Biotechnology industry median of 3.29. Strategic Partners AS's overall GF Score™ is 27/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Strategic Partners AS (CHIX:STRAPC), the current Price-to-Tangible-Book is 18.23 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Strategic Partners A/S enters into strategic partnerships with companies with potential, where the company can take an active ownership and create value through its competencies. Additionally, the company takes part in other equity investments and properties, etc., to generate returns.
27GF Score
Get the complete analysis for CHIX:STRAPC
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:STRAPC has been successfully added to your 
